Novo Nordisk sues Hims & Hers to block compounded semaglutide amid FDA scrutiny

Legal showdown over semaglutide

Novo Nordisk sues Hims & Hers, seeks permanent injunction

Novo Nordisk is escalating a legal fight against telehealth firm Hims & Hers by suing to permanently block sales of a compounded oral semaglutide product it says infringes patents and endangers patients. The Danish drugmaker asks a U.S. court for injunctive relief and damages on grounds that Hims has mass‑marketed cheaper knock‑offs of its Wegovy obesity treatment without the safety, efficacy and regulatory verification required for approved GLP‑1 therapies. Novo Nordisk frames the action as necessary to protect innovation and public safety, saying mass compounding for broad commercial distribution undercuts the regulatory framework that governs prescription medicines.

Hims & Hers announces withdrawal after regulator pressure

Hims & Hers is stopping access to its compounded semaglutide pill after what it describes as “constructive conversations with stakeholders” and scrutiny from the U.S. Food and Drug Administration. The company had sought to offer a lower‑cost oral alternative to branded products, but federal regulators signal enforcement and the FDA announces steps to restrict ingredient access and refer the matter to the Department of Justice. Novo Nordisk and regulators point to patents protecting semaglutide through 2032 and warn that compounded copies can lack verified quality controls, creating potential safety risks for patients.

Dispute highlights compounding loophole and safety concerns

The case crystallises tensions over a regulatory loophole that allows compounding when branded treatments are scarce and the surge in demand for GLP‑1 weight‑loss medicines. Novo Nordisk says it has ramped manufacturing to eliminate shortages for its Wegovy pill, while also estimating widespread use of compounded GLP‑1 products. The company is seeking judicial recognition that mass commercial compounding violates patent rights and public trust, and it frames litigation as part of a broader effort to preserve regulatory rigor around novel obesity therapies.

Regulatory and industry ripple

Regulators and industry players such as Eli Lilly are intensifying scrutiny of compounded GLP‑1 offerings, arguing enforcement is needed to clarify safety, intellectual property and commercial boundaries. The move may slow the spread of lower‑cost oral alternatives at least temporarily as courts and agencies determine how to apply existing patent and drug‑safety laws to mass compounding.

Wider implications for access debates

The dispute underscores how rapidly the booming obesity‑drug market is prompting legal and policy fights over pricing, access and innovation. Hims & Hers frames its withdrawal as a pause driven by dialogue with stakeholders, but the case remains a developing test of how regulators and manufacturers will balance patient access with patented, approved therapies.